Cargando…

An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy

Phosphoserine aminotransferase 1 (PSAT1) may be an oncogene that plays an important role in various cancer types. However, there are still many gaps in the expression of PSAT1 gene and its biological impact in different types of tumors. Here, we performed an integrated pan-cancer analysis to explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Mingtao, Cui, Huanhuan, Tu, Wenjing, Li, Liangdong, Gao, Yang, Chen, Lei, Li, Deheng, Chen, Xin, Xu, Fengfeng, Zhou, Changshuai, Cao, Yiqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465327/
https://www.ncbi.nlm.nih.gov/pubmed/36105075
http://dx.doi.org/10.3389/fgene.2022.975381
_version_ 1784787771704999936
author Feng, Mingtao
Cui, Huanhuan
Tu, Wenjing
Li, Liangdong
Gao, Yang
Chen, Lei
Li, Deheng
Chen, Xin
Xu, Fengfeng
Zhou, Changshuai
Cao, Yiqun
author_facet Feng, Mingtao
Cui, Huanhuan
Tu, Wenjing
Li, Liangdong
Gao, Yang
Chen, Lei
Li, Deheng
Chen, Xin
Xu, Fengfeng
Zhou, Changshuai
Cao, Yiqun
author_sort Feng, Mingtao
collection PubMed
description Phosphoserine aminotransferase 1 (PSAT1) may be an oncogene that plays an important role in various cancer types. However, there are still many gaps in the expression of PSAT1 gene and its biological impact in different types of tumors. Here, we performed an integrated pan-cancer analysis to explore the potential molecular mechanisms of PSAT1 in cancers. We found that most human tumors express higher levels of PSAT1 than normal tissues, and that higher PSAT1 expression is associated with worse prognosis in Lung adenocarcinoma (LUAD), Pan-kidney cohort (KIPAN) and breast invasive carcinoma (BRCA), etc. In BRCA cases, the prognosis of patients with altered PSAT1 was worse than that of patients without alteration. In addition, PSAT1 hypermethylation is associated with T cell dysfunction and shortened survival time in BRCA. The Gene Set Enrichment Analysis (GSEA) analysis showed that PSAT1 can be enriched into the classic signaling pathways of cancer such as mTORC1 signaling, MYC targets and JAK STAT3. Further analysis demonstrated that PSAT1 was enriched in immune related signaling pathways in LUAD and BRCA. The results of immunoassay showed that PSAT1 was associated with immune cell infiltration in multiple cancer species. Furthermore, expression of PSAT1 was correlated with both tumor mutational burden (TMB) and microsatellite instability (MSI) in BRCA. Additionally, a remarkable correlation was found between PSAT1 expression and TMB in LUAD, and the expression of PSAT1 was negatively correlated with the Tumor Immune Dysfunction and Exclusion (TIDE) value, suggesting a good effect of immunotherapy. Together, these data suggest that PSAT1 expression is associated with the clinical prognosis, DNA methylation, gene mutations, and immune cell infiltration, contributing to clarify the role of PSAT1 in tumorigenesis from a variety of perspectives. What’s more, PSAT1 may be a new biomarker for survival and predicting the efficacy of immunotherapy for LUAD and BRCA.
format Online
Article
Text
id pubmed-9465327
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94653272022-09-13 An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy Feng, Mingtao Cui, Huanhuan Tu, Wenjing Li, Liangdong Gao, Yang Chen, Lei Li, Deheng Chen, Xin Xu, Fengfeng Zhou, Changshuai Cao, Yiqun Front Genet Genetics Phosphoserine aminotransferase 1 (PSAT1) may be an oncogene that plays an important role in various cancer types. However, there are still many gaps in the expression of PSAT1 gene and its biological impact in different types of tumors. Here, we performed an integrated pan-cancer analysis to explore the potential molecular mechanisms of PSAT1 in cancers. We found that most human tumors express higher levels of PSAT1 than normal tissues, and that higher PSAT1 expression is associated with worse prognosis in Lung adenocarcinoma (LUAD), Pan-kidney cohort (KIPAN) and breast invasive carcinoma (BRCA), etc. In BRCA cases, the prognosis of patients with altered PSAT1 was worse than that of patients without alteration. In addition, PSAT1 hypermethylation is associated with T cell dysfunction and shortened survival time in BRCA. The Gene Set Enrichment Analysis (GSEA) analysis showed that PSAT1 can be enriched into the classic signaling pathways of cancer such as mTORC1 signaling, MYC targets and JAK STAT3. Further analysis demonstrated that PSAT1 was enriched in immune related signaling pathways in LUAD and BRCA. The results of immunoassay showed that PSAT1 was associated with immune cell infiltration in multiple cancer species. Furthermore, expression of PSAT1 was correlated with both tumor mutational burden (TMB) and microsatellite instability (MSI) in BRCA. Additionally, a remarkable correlation was found between PSAT1 expression and TMB in LUAD, and the expression of PSAT1 was negatively correlated with the Tumor Immune Dysfunction and Exclusion (TIDE) value, suggesting a good effect of immunotherapy. Together, these data suggest that PSAT1 expression is associated with the clinical prognosis, DNA methylation, gene mutations, and immune cell infiltration, contributing to clarify the role of PSAT1 in tumorigenesis from a variety of perspectives. What’s more, PSAT1 may be a new biomarker for survival and predicting the efficacy of immunotherapy for LUAD and BRCA. Frontiers Media S.A. 2022-08-29 /pmc/articles/PMC9465327/ /pubmed/36105075 http://dx.doi.org/10.3389/fgene.2022.975381 Text en Copyright © 2022 Feng, Cui, Tu, Li, Gao, Chen, Li, Chen, Xu, Zhou and Cao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Feng, Mingtao
Cui, Huanhuan
Tu, Wenjing
Li, Liangdong
Gao, Yang
Chen, Lei
Li, Deheng
Chen, Xin
Xu, Fengfeng
Zhou, Changshuai
Cao, Yiqun
An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
title An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
title_full An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
title_fullStr An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
title_full_unstemmed An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
title_short An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy
title_sort integrated pan-cancer analysis of psat1: a potential biomarker for survival and immunotherapy
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465327/
https://www.ncbi.nlm.nih.gov/pubmed/36105075
http://dx.doi.org/10.3389/fgene.2022.975381
work_keys_str_mv AT fengmingtao anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT cuihuanhuan anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT tuwenjing anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT liliangdong anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT gaoyang anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT chenlei anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT lideheng anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT chenxin anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT xufengfeng anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT zhouchangshuai anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT caoyiqun anintegratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT fengmingtao integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT cuihuanhuan integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT tuwenjing integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT liliangdong integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT gaoyang integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT chenlei integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT lideheng integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT chenxin integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT xufengfeng integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT zhouchangshuai integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy
AT caoyiqun integratedpancanceranalysisofpsat1apotentialbiomarkerforsurvivalandimmunotherapy